Status: Recruiting
A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study
This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.
Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: YS Life Science Co., Ltd.Updated: Jun 22, 2026Locations: 16
Eligibility criteria
Subjects willing and able to provide voluntary informed consent and to follow pr... [+14]
Female subjects with positive pregnancy test or lactating or planning a pregnanc... [+24]